• Find people
• Intranet

News

04/03/2026 - Events

CORDELIA Project: advancing genetic prediction of cardiovascular disease

On February 26 and 27, the 3rd Meeting of the Scientific Committee of the CORDELIA project (www.cordeliaproject.net) was held at the headquarters of the Fundació IMIM - Hospital del Mar Research Institute, at the Barcelona Biomedical Research Park (PRBB). This collaborative initiative brings together 35 Spanish cohorts and compiles data from 197,000 participants, with an average follow-up of more than 15 years, and is now marking three years of development.

The CORDELIA project involves 23 groups from CIBERCV, CIBERESP, CIBERSAM, CIBERFES, CIBEROBN, CIBERER and CIBERDEM.

The meeting brought together nearly 70 researchers in person and an average of 12 online attendees per day, consolidating CORDELIA as one of the most relevant collaborative platforms in Spain in the fields of cardiovascular epidemiology and genetics.

Three years of progress in cardiovascular research

The meeting opened with an institutional welcome and a review of the project’s three-year track record, delivered by Dr. Jaume Marrugat, who highlighted CORDELIA’s multidisciplinary, collaborative and transgenerational nature, as well as its potential to generate important scientific contributions in the near future.

Next, Dr. Roberto Elosua gave the keynote lecture on the genetics of coronary disease, reviewing the main advances in understanding the genetic basis of coronary risk and its potential clinical application.

During the first day, the activities carried out by the project’s different committees -Statistics, Genetics, Publications and Event definition- were also presented, and a roundtable was held focusing on the role of lifestyle and environmental pollution in cardiovascular health, and their relevance for CORDELIA’s future research lines. Topics addressed included the Mediterranean diet, physical activity, risk functions, cognitive decline and exposure to pollutants, highlighting CORDELIA’s comprehensive and multidisciplinary approach.

New publications and preliminary results

The second day focused on the presentation of publications and ongoing studies. One of the most anticipated moments was the presentation of the CORDELIA GWAS (Genome-Wide Association Study) with a preliminary analysis on coronary mortality. The rationale, methods and preliminary results of the genomic analysis were presented and discussed. These results represent a decisive step toward identifying genetic variants associated with coronary mortality in the Spanish population and in southern Europe.

Looking ahead: new strategic projects

The meeting concluded with the presentation of projects funded by the FIS and the European Union, which are strategic and will shape CORDELIA’s next stage

• REDAMCOR, focused on the GWAS of heart failure.
• HIPATIA, which analyzes hypertension, inflammation and renal function in cardiovascular events through Mendelian randomization.
• LIGHT, on holistic interactions between lifestyle and genotype in mortality.

The final discussion highlighted the strength of the collaborative network built over these three years and the commitment of its researchers to cardiovascular research

of high quality, aimed both at generating knowledge and at its future clinical translation.

Recognition of the CORDELIA team

At the closing of the meeting, Dr. Jaume Marrugat underscored the importance of coronary disease, which has remained the leading single cause of death worldwide over the last 30 years, and thanked the CORDELIA team for the effort made and their commitment to the project. He acknowledged the contribution of different individuals and teams within the consortium, highlighting the key role of coordination, data harmonization, genotyping, and the logistical and communication support for scientific meetings.

With this third scientific meeting, CORDELIA reaffirms its role as a benchmark project in the integrated study of genetics, epidemiology and lifestyles in cardiovascular disease, consolidating an active and cohesive scientific community that will continue to provide evidence to improve the prevention and prognosis of cardiovascular diseases in our setting.

More news